About Viscosupplementation
Viscosupplementation is a minimally invasive treatment for knee osteoarthritis. It involves the injection of hyaluronic acid into a knee joint to assist the viscous properties of synovial fluid. The procedure increases the joint’s functioning and reduces pain. Intra-articular viscosupplementation with hyaluronic acid is gaining acceptance as it is a non-invasive procedure compared to knee replacement. It is categorized into three product segments –– single-injection cycle, three-injection cycle, and five-injection cycle.
Technavio’s analysts forecast the global Viscosupplementation market to grow at a CAGR of 6.23% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global Viscosupplementation market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of products in different regions.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Viscosupplementation Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Sanofi
• Anika Therapeutics
• Seikagaku
• Fidia Farmaceutici
• Ferring Pharmaceuticals
Other prominent vendors
• Allergan
• Contipro Biotech
• DePuy Synthes
• F. Hoffmann-La Roche
• Galderma
• HTL Biotechnology
• Hyaltech
• Expanscience Laboratoires
• Lifecore Biomedical
• Lipo Chemicals
• Merz Aesthetics
• Mylan
• Nordic Drugs
• Shandong Freda Biochem
• Shanghai Jingfeng Pharmaceutical
• Smith & Nephew
• TEIJIN PHARMA
• TRB Chemedica International
Market driver
• Fast-growing geriatric population
• For a full, detailed list, view our report
Market challenge
• Threat from substitutes
• For a full, detailed list, view our report
Market trend
• Increasing patient preference for single-injection cycle
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Vendor analysis
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Market segmentation by products
• Market overview
• Single-injection cycle market
• Three-injection cycle market
• Five-injection cycle market
PART 07: Geographical segmentation
• Market overview
• Viscosupplementation market in Americas
• Viscosupplementation market in EMEA
• Viscosupplementation market in APAC
PART 08: Market drivers
PART 09: Impact of drivers
PART 10: Market challenges
PART 11: Impact of drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
• Competitive scenario
• Market vendor ranking analysis 2015
PART 14: Key vendor analysis
• Geographic presence: Key vendor analysis
• Sanofi
• Anika Therapeutics
• Seikagaku
• Fidia Farmaceutici
• Ferring Pharmaceuticals
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
PART 16: Explore Technavio
List of Exhibits
Exhibit 01: Key countries
Exhibit 02: Global viscosupplementation market segmentation: Overview
Exhibit 03: Product offerings
Exhibit 04: Snapshot: Global viscosupplementation market
Exhibit 05: Global viscosupplementation market: Key impacting factors
Exhibit 06: Growth perspective in developed and emerging markets
Exhibit 07: Global viscosupplementation market 2015-2020 ($ billions)
Exhibit 08: Impact of various factors on global viscosupplementation market
Exhibit 09: Five forces analysis
Exhibit 10: Global viscosupplementation market by product type 2015 and 2020
Exhibit 11: Global viscosupplementation market segmentation by product type 2015-2020 (% share)
Exhibit 12: Impact of product segments in global viscosupplementation market
Exhibit 13: Global single-injection cycle market 2015-2020 ($ billions)
Exhibit 14: Global three-injection cycle market 2015-2020 ($ billions)
Exhibit 15: Global five-injection cycle market 2015-2020
Exhibit 16: Global viscosupplementation market by five-injection cycle procedure 2015-2020 ($ billions)
Exhibit 17: Global viscosupplementation market by geography 2015 and 2020 (% share)
Exhibit 18: Global viscosupplementation market by geography 2015-2020 (% share)
Exhibit 19: Snapshot: Global viscosupplementation market by geography
Exhibit 20: Viscosupplementation market in Americas 2015-2020 ($ billions)
Exhibit 21: Viscosupplementation market in EMEA ($ billions)
Exhibit 22: Viscosupplementation market in APAC ($ billions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Strategic success factor of companies
Exhibit 26: Competitive parameters in global viscosupplementation market
Exhibit 27: Global viscosupplementation market vendor analysis 2015
Exhibit 28: Regional analysis of key vendors
Exhibit 29: Sanofi profile
Exhibit 30: Sanofi strength analysis
Exhibit 31: Sanofi growth strategy matrix
Exhibit 32: Sanofi: Opportunity assessment
Exhibit 33: Anika Therapeutics profile
Exhibit 34: Anika Therapeutics strength analysis
Exhibit 35: Anika Therapeutics growth strategy matrix
Exhibit 36: Anika Therapeutics: Opportunity assessment
Exhibit 37: Seikagaku profile
Exhibit 38: Seikagaku strength analysis
Exhibit 39: Seikagaku growth strategy matrix
Exhibit 40: Seikagaku: Opportunity assessment
Exhibit 41: Fidia Farmaceutici profile
Exhibit 42: Fidia Farmaceutici strength analysis
Exhibit 43: Fidia Farmaceutici growth strategy matrix
Exhibit 44: Fidia Farmaceutici: Opportunity assessment
Exhibit 45: Ferring Pharmaceuticals profile
Exhibit 46: Ferring Pharmaceuticals strength analysis
Exhibit 47: Ferring Pharmaceuticals growth strategy matrix
Exhibit 48: Ferring Pharmaceuticals: Opportunity assessment
